Chorea
10
2
2
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
10.0%
1 terminated out of 10 trials
85.7%
-0.8% vs benchmark
20%
2 trials in Phase 3/4
67%
4 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (10)
Deep Brain Stimulation (DBS) MatchMaker
A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes
Registry and Natural History of Epilepsy-Dyskinesia Syndromes
Risperidone for the Treatment of Huntington's Disease Involuntary Movements
First Time Use of SD-809 in Huntington Disease
Citalopram to Enhance Cognition in HD
Atomoxetine and Huntington's Disease
Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea
Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia
Treatment of Huntington's Chorea With Amantadine